MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

78.99 +0.31 (+0.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum ↗
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in... 
Via MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Soars 70% After Hours on REDEMPLO Launch Momentum and Strong Q2 Earnings Beat ↗
Via Chartmill
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Presents a High-Growth, Technical Breakout Opportunity ↗
Via Chartmill
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reports Profitable Quarter on Strong Drug Launch ↗
Via Chartmill
News headline image
Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near ↗
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief Executive Officer Chris Anzalone said during a... 
Via MarketBeat
News headline image
Arrowhead (ARWR) Q2 2026 Earnings Transcript ↗
Arrowhead (ARWR) Q2 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Emerges as a Growth Stock with a Constructive Technical Setup ↗
Arrowhead Pharmaceuticals (ARWR) combines strong revenue growth and profitability with a bullish technical chart pattern, signaling a potential breakout for this RNAi therapy developer. 
Via Chartmill
News headline image
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics
CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ: SRPT) skyrocketed 35% in early trading today, reaching levels not seen since the company’s early days in Duchenne Muscular... 
Via MarketMinute
News headline image
Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years.... 
Via MarketMinute
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Via Investor Brand Network
Topics Intellectual Property
News headline image
The Great Rotation: How the 'One Big Beautiful Bill Act' is Igniting a Small-Cap Renaissance
The U.S. financial landscape is undergoing a tectonic shift as the "One Big Beautiful Bill Act" (OBBBA), signed into law on July 4, 2025, begins to exert its full influence on the equity markets. For... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
From BioMedWire
Via GlobeNewswire
News headline image
Arrowhead (ARWR) Q1 2026 Earnings Call Transcript ↗
Arrowhead (ARWR) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ciena’s AI-Driven Return: Networking Giant to Join S&P 500 Benchmark
In a move signaling the stock market’s continued embrace of the artificial intelligence infrastructure trade, S&P Dow Jones Indices announced late Wednesday that Ciena Corporation (NYSE: CIEN) will... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million ↗
This biotech firm develops RNAi therapeutics for rare and serious diseases, leveraging clinical partnerships to advance its pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million? ↗
Arrowhead Pharmaceuticals, a leader in RNAi therapeutics, reported a significant insider sale amid a year of exceptional stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story